Since the CD44-RhoA-YAP signaling pathway blockade could effectively protect matrix stiffness-triggered fibroblast activation in vitro, we examined whether it could provide a potential therapeutic benefit for postponing the development of silicosis in mice. This evidence concerns the gene RHOA and silicosis.